The EMEA (European Medicines Agency) have given a positive boost to Galvus, the Novartis AG type 2 diabetes drug to be used in conjunction with other drugs.
The decision was part of a spate of positive verdicts. Two Pfizer drugs, HIV drug Celsentri and anti-fungal Ecalta were also approved. In order for all of these drugs to come to market the European Commission needs to endorse the verdict, a process that typically takes several months.
Other drugs, including Novatis offering Aclasta were also approved. Avasti, a Roche cancer drug, was cleared. GlaxoSmithKline PLC was granted extensions to use their drug Telzir as an HIV treatment in children and adolescents. The approval of Galvus is likely to improve the financial situation and morale at Novartis.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…